Pharma Mar Statistics
Total Valuation
Pharma Mar has a market cap or net worth of EUR 1.43 billion. The enterprise value is 1.32 billion.
Market Cap | 1.43B |
Enterprise Value | 1.32B |
Important Dates
The next estimated earnings date is Friday, April 25, 2025.
Earnings Date | Apr 25, 2025 |
Ex-Dividend Date | Jun 12, 2024 |
Share Statistics
Pharma Mar has 17.57 million shares outstanding. The number of shares has decreased by -1.98% in one year.
Current Share Class | n/a |
Shares Outstanding | 17.57M |
Shares Change (YoY) | -1.98% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 11.77% |
Owned by Institutions (%) | 8.64% |
Float | 12.74M |
Valuation Ratios
The trailing PE ratio is 54.51 and the forward PE ratio is 34.89. Pharma Mar's PEG ratio is 0.31.
PE Ratio | 54.51 |
Forward PE | 34.89 |
PS Ratio | 8.14 |
PB Ratio | 6.85 |
P/TBV Ratio | 6.88 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | 0.31 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 108.57, with an EV/FCF ratio of -147.27.
EV / Earnings | 50.67 |
EV / Sales | 7.57 |
EV / EBITDA | 108.57 |
EV / EBIT | 204.64 |
EV / FCF | -147.27 |
Financial Position
The company has a current ratio of 3.03, with a Debt / Equity ratio of 0.25.
Current Ratio | 3.03 |
Quick Ratio | 2.29 |
Debt / Equity | 0.25 |
Debt / EBITDA | 4.19 |
Debt / FCF | -5.68 |
Interest Coverage | 2.62 |
Financial Efficiency
Return on equity (ROE) is 13.00% and return on invested capital (ROIC) is 1.63%.
Return on Equity (ROE) | 13.00% |
Return on Assets (ROA) | 1.17% |
Return on Invested Capital (ROIC) | 1.63% |
Return on Capital Employed (ROCE) | 2.42% |
Revenue Per Employee | 349,710 |
Profits Per Employee | 52,250 |
Employee Count | 500 |
Asset Turnover | 0.51 |
Inventory Turnover | 0.18 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +179.92% in the last 52 weeks. The beta is -0.05, so Pharma Mar's price volatility has been lower than the market average.
Beta (5Y) | -0.05 |
52-Week Price Change | +179.92% |
50-Day Moving Average | 91.15 |
200-Day Moving Average | 65.22 |
Relative Strength Index (RSI) | 32.98 |
Average Volume (20 Days) | 50,161 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharma Mar had revenue of EUR 174.86 million and earned 26.13 million in profits. Earnings per share was 1.49.
Revenue | 174.86M |
Gross Profit | 166.67M |
Operating Income | 6.47M |
Pretax Income | 11.99M |
Net Income | 26.13M |
EBITDA | 10.07M |
EBIT | 6.47M |
Earnings Per Share (EPS) | 1.49 |
Balance Sheet
The company has 154.53 million in cash and 51.08 million in debt, giving a net cash position of 103.45 million or 5.89 per share.
Cash & Cash Equivalents | 154.53M |
Total Debt | 51.08M |
Net Cash | 103.45M |
Net Cash Per Share | 5.89 |
Equity (Book Value) | 208.36M |
Book Value Per Share | 11.86 |
Working Capital | 167.55M |
Cash Flow
In the last 12 months, operating cash flow was 6.03 million and capital expenditures -15.02 million, giving a free cash flow of -8.99 million.
Operating Cash Flow | 6.03M |
Capital Expenditures | -15.02M |
Free Cash Flow | -8.99M |
FCF Per Share | -0.51 |
Margins
Gross margin is 95.32%, with operating and profit margins of 3.70% and 14.94%.
Gross Margin | 95.32% |
Operating Margin | 3.70% |
Pretax Margin | 6.85% |
Profit Margin | 14.94% |
EBITDA Margin | 5.76% |
EBIT Margin | 3.70% |
FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.65, which amounts to a dividend yield of 0.80%.
Dividend Per Share | 0.65 |
Dividend Yield | 0.80% |
Dividend Growth (YoY) | 23.46% |
Years of Dividend Growth | 1 |
Payout Ratio | 43.71% |
Buyback Yield | 1.98% |
Shareholder Yield | 2.78% |
Earnings Yield | 1.83% |
FCF Yield | -0.63% |
Stock Splits
The last stock split was on July 22, 2020. It was a reverse split with a ratio of 0.0833333333.
Last Split Date | Jul 22, 2020 |
Split Type | Reverse |
Split Ratio | 0.0833333333 |
Scores
Pharma Mar has an Altman Z-Score of 5.16.
Altman Z-Score | 5.16 |
Piotroski F-Score | n/a |